Public Employees Retirement System of Ohio Boosts Position in Elanco Animal Health Incorporated $ELAN

Posted by George Bondi on Sep 1st, 2026

Public Employees Retirement System of Ohio raised its position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 113.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 330,645 shares of the company’s stock after acquiring an additional 175,412 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Elanco Animal Health were worth $8,137,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ELAN. BlackRock Inc. bought a new stake in shares of Elanco Animal Health during the 2nd quarter valued at about $1,202,198,000. Primecap Management Co. CA purchased a new position in shares of Elanco Animal Health in the second quarter worth approximately $1,118,402,000. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Elanco Animal Health by 11.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Elanco Animal Health by 1.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after buying an additional 373,869 shares during the period. Finally, UBS Group AG grew its position in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 0.4%

Shares of ELAN opened at $24.01 on Tuesday. The business’s 50 day moving average is $24.62 and its 200 day moving average is $23.99. The company has a market capitalization of $12.00 billion, a PE ratio of -58.56, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ELAN shares. Citigroup increased their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. KeyCorp upped their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. UBS Group raised their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, TD Cowen lifted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Read Our Latest Report on Elanco Animal Health

Insider Activity at Elanco Animal Health

In related news, insider Shiv O’neill purchased 3,998 shares of Elanco Animal Health stock in a transaction on Tuesday, August 18th. The shares were bought at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the acquisition, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael J. Harrington acquired 5,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were bought at an average cost of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director directly owned 131,451 shares in the company, valued at approximately $2,868,260.82. The trade was a 3.95% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 63,198 shares of company stock valued at $1,473,109 in the last ninety days. Corporate insiders own 1.14% of the company’s stock.

About Elanco Animal Health

(Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.